Ultragenyx Pharmaceutical Inc. 8-K Filing
Ticker: RARE · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ultragenyx Pharmaceutical Inc. (ticker: RARE) to the SEC on Dec 29, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select).
How long is this filing?
Ultragenyx Pharmaceutical Inc.'s 8-K filing is 3 pages with approximately 968 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 968 words · 4 min read · ~3 pages · Grade level 17.5 · Accepted 2025-12-29 08:45:24
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
Filing Documents
- rare-20251229.htm (8-K) — 53KB
- 0001193125-25-332422.txt ( ) — 154KB
- rare-20251229.xsd (EX-101.SCH) — 23KB
- rare-20251229_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 29, 2025, Ultragenyx Pharmaceutical Inc. (the "Company") announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta ("OI"). Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively. Both studies achieved the secondary endpoints of improvements in bone mineral density ("BMD") against comparators. There was no change in the safety profile observed. Orbit and Cosmic Results In the Orbit study, participants experienced statistically significant and substantial improvements in BMD compared to placebo, at levels consistent with the treatment effect observed in the Phase 2 portion of the study. These BMD changes were not accompanied by a corresponding reduction in annualized fracture rates and there was a low fracture rate in the placebo group. In the pediatric Cosmic study, patients had a substantially higher baseline fracture rate compared to the patients enrolled in Orbit. In this younger patient population, meaningful improvements in BMD were associated with a reduction in annualized fracture rate for setrusumab treated patients compared to bisphosphonate treated patients, though the reduction did not meet statistical significance. The Company is conducting additional analyses on the data across both studies, including on other bone health and clinical endpoints beyond fractures to assess next steps for the program given the totality of these data. The Company will implement expense reductions The Company is evaluating its planned operations and will promptly define and implement significant expense reductions. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical, Inc. Date: December 29, 2025 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy